Adult
Baloxavir
Warning
General Information
Cap-dependent endonuclease inhibitor
Restricted formulary antimicrobial: For details see OUH netFormulary
Age restriction: 12 years – 64 years
For all information regarding interactions, contraception, pregnancy and breastfeeding and additional information, see BNF and Summary of Product Characteristics (SPC).
Standard dose
Standard dose
|
Patient body weight |
Oral baloxavir marboxil dose |
|
80kg or more |
80mg po single dose |
|
20kg upto 80kg |
40mg po single dose |
Renal and hepatic impairment
Renal impairment
- No dose adjustment required.
Hepatic impairment
- Mild or moderate hepatic impairment (Child-Pugh class A or B): No dose adjustment is required.
- Severe hepatic impairment (Child-Pugh class C): Safety and efficacy have not been established in this patient group.
References
- UK Health Security Agency (2025. Updated 23/1/26). Guidance on use of antiviral agents for the treatment and prophylaxis of seasonal influenza. [online] Available at: https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents/guidance-on-use-of-antiviral-agents-for-the-treatment-and-prophylaxis-of-seasonal-influenza. [Accessed 31 Jan 2026]
- BNF. (n.d.). Baloxavir marboxil. [online] Available at: https://bnf.nice.org.uk/drugs/baloxavir-marboxil/ [Accessed 31 Jan 2026].
- Roche Products Limited. Summary of Product Characteristics. Xofluza 40 mg film coated tablets [online]. Last revision of the text 29/12/25. Available at: https://www.medicines.org.uk/emc/product/14764/smpc#gref [Accessed 31 Jan 2026].